GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Ending Cash Position
Switch to:

Biogen (BUE:BIIB) Ending Cash Position

: ARS572,539 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's Ending Cash Position for the quarter that ended in Mar. 2023 was ARS572,539 Mil.

Biogen's quarterly Ending Cash Position increased from Sep. 2022 (ARS510,725 Mil) to Dec. 2022 (ARS573,246 Mil) but then declined from Dec. 2022 (ARS573,246 Mil) to Mar. 2023 (ARS572,539 Mil).

Biogen's annual Ending Cash Position increased from Dec. 2020 (ARS108,333 Mil) to Dec. 2021 (ARS228,379 Mil) and increased from Dec. 2021 (ARS228,379 Mil) to Dec. 2022 (ARS573,246 Mil).


Biogen Ending Cash Position Historical Data

The historical data trend for Biogen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46,173.55 174,162.34 108,333.05 228,378.78 573,245.63

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Ending Cash Position Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187,825.94 318,465.38 510,724.61 573,245.63 572,539.42

Biogen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biogen's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=379123.699+194121.93
=573,246

Biogen's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=675482.73+-102943.307
=572,539


Biogen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines